secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001628280-24-035593
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex Q2 net sales up 12% to $22.7M; adjusted EBITDA positive $1.6M
-----------------------------------------------------------------------

- Total net sales $22.7M (+12% YoY); Tru Niagen sales $18.6M (+10% YoY).
- Gross margin 60.2%; operating expenses down $0.7M YoY to $13.9M.
- Net loss approximately breakeven, a $2.2M improvement vs Q2 2023 loss of $2.2M.
- Adjusted EBITDA improved to $1.6M from $0.2M in prior year quarter.
- FDA Orphan Drug and Rare Pediatric Disease Designation for nicotinamide riboside chloride in Ataxia Telangiectasia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024035593/0001628280-24-035593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024035593/cdxc-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-035593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer